GILEAD SCIENCES, INC. is 18.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($151.05 B vs $8.36 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HALO | GILD |
|---|---|---|
| Market cap | $8.36 B | $151.05 B |
| US-listed rank | #1040 | #99 |
| Revenue (latest FY) | $1.40B | $29.44B |
| Net income (latest FY) | $316.89M | $8.51B |
| Net margin | 22.7% | 28.9% |
| P/E (trailing FY) | 26.4 | 17.7 |
| SEC filings | 1,481 | 981 |
GILEAD SCIENCES, INC. is 18.1x more valuable than HALOZYME THERAPEUTICS, INC. by market capitalization ($151.05 B vs $8.36 B).
In their latest fiscal years, HALOZYME THERAPEUTICS, INC. reported $1.40B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: HALOZYME THERAPEUTICS, INC. and GILEAD SCIENCES, INC., or browse the full rankings.